POZ: Three-prong approach may clear HIV in infants
Researchers have identified a three-pronged therapy strategy that may limit the HIV reservoir in infants, potentially leading to a functional cure. The approach combines antiretroviral therapy, neutralizing antibodies, and CCR5-blocking antibodies.
Why it matters
This research offers a promising new pathway for treating newborns exposed to HIV and potentially improving outcomes for adults.
A three-prong strategy combining antiretroviral therapy, broadly neutralizing antibodies and the CCR5-blocking antibody leronlimab may limit the size of the HIV reservoir in infants, potentially paving the way for a functional cure, according to research published in Nature Microbiology .
“These findings suggest a synergy between broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade for preventing viral reservoir establishment and offer potential improvements over current therapies for newborns exposed to [HIV],” the researchers wrote.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in